[HTML][HTML] Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations

G Ferraioli, VWS Wong, L Castera, A Berzigotti… - Ultrasound in medicine …, 2018 - Elsevier
Abstract The World Federation for Ultrasound in Medicine and Biology has produced these
guidelines for the use of elastography techniques in liver diseases. For each available …

Hepatic microcirculation and mechanisms of portal hypertension

J Gracia-Sancho, G Marrone… - Nature reviews …, 2019 - nature.com
The liver microcirculatory milieu, mainly composed of liver sinusoidal endothelial cells
(LSECs), hepatic stellate cells (HSCs) and hepatic macrophages, has an essential role in …

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update

A Berzigotti, E Tsochatzis, J Boursier, L Castera… - Journal of …, 2021 - Elsevier
Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo …

C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan… - The lancet, 2019 - thelancet.com
Background Clinical decompensation of cirrhosis is associated with poor prognosis.
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

P Angeli, M Bernardi, C Villanueva, C Francoz… - Journal of …, 2018 - Elsevier
The natural history of cirrhosis is characterised by an asymptomatic compensated phase
followed by a decompensated phase, marked by the development of overt clinical signs, the …

Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of …

J Neuberger, J Patel, H Caldwell, S Davies, V Hebditch… - Gut, 2020 - gut.bmj.com
Liver biopsy is required when clinically important information about the diagnosis, prognosis
or management of a patient cannot be obtained by safer means, or for research purposes …

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek… - Hepatology, 2018 - journals.lww.com
Emerging studies have suggested that the Hippo pathway is involved in the tumorigenesis of
hepatocellular carcinoma (HCC). However, the key regulator of the Hippo pathway in liver …

[HTML][HTML] HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease

G Semmler, EL Meyer, K Kozbial, P Schwabl… - Journal of …, 2022 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) is a major cause of morbidity and
mortality in patients with advanced chronic liver disease (ACLD) caused by chronic hepatitis …

Fibrosis regression after eradication of hepatitis C virus: from bench to bedside

DC Rockey, SL Friedman - Gastroenterology, 2021 - Elsevier
Hepatitis C virus (HCV) infection and its complications have been the major cause of
cirrhosis and its complications for several decades in the Western world. Until recently …

[HTML][HTML] Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity

LAP Krassenburg, R Maan, A Ramji, MP Manns… - Journal of …, 2021 - Elsevier
Background & Aims HCV-infected patients with cirrhosis achieve high sustained virological
response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic …